23.86

3.16% 0.73

Spyre Therapeutics Inc (SYRE)

Overview News Price History Financials Discussions Forecast

Spyre Therapeutics Inc stock is traded at $23.86, with a volume of 1.22M. It is up +3.16% in the last 24 hours and down -13.24% over the past month. Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Previous Close:

$23.13

Open:

$22.9

24h Volume:

1.22M

Relative Volume:

2.08

Market Cap:

$1.40B

Revenue:

$1.23M

Net Income/Loss:

$-214.90M

P/E Ratio:

EPS:

Net Cash Flow:

$-151.25M

1W Performance:

-1.08%

1M Performance:

-13.24%

6M Performance:

-6.91%

1Y Performance:

+53.44%

1-Day Range:

$22.62

$24.88

1-Week Range:

$22.57

$25.67

52-Week Range:

$15.60

$47.97

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name

Spyre Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

(617) 651-5940

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SYRE's Discussions on Twitter

Compare SYRE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SYRE Spyre Therapeutics Inc	23.86	1.40B	1.23M	-214.90M	-151.25M	-4.1222
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-04-24	Initiated	Wedbush	Outperform
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-20-23	Initiated	BTIG Research	Buy
Dec-11-23	Initiated	Guggenheim	Buy
Dec-11-23	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
Mar-21-19	Initiated	JP Morgan	Overweight
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform
Mar-14-18	Reiterated	Needham	Buy

View All

Spyre Therapeutics Inc Stock (SYRE) Latest News

Dec 20, 2024

State Street Corp Buys 131,896 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,680 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Dec 20, 2024

Dec 18, 2024

Spyre Therapeutics Earns Coveted Spot in Nasdaq Biotechnology Index, Marking IBD Innovation Leadership - StockTitan

Dec 18, 2024

Dec 17, 2024

Evercore ISI Group Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - MSN

Dec 17, 2024

Dec 16, 2024

Jones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold Recommendation - MSN

Dec 16, 2024

Dec 12, 2024

The Manufacturers Life Insurance Company Has $1.28 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Dec 12, 2024

Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE) - Seeking Alpha

Dec 12, 2024

Wellington Management Group LLP Has $44.33 Million Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 12, 2024

Dec 10, 2024

Charles Schwab Investment Management Inc. Has $9.80 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 10, 2024

Dec 07, 2024

Spyre Therapeutics Announces Grants of Inducement Awards - The Eastern Progress Online

Dec 07, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Janus Henderson Group PLC - MarketBeat

Dec 07, 2024

Dec 04, 2024

61,256 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Cinctive Capital Management LP - MarketBeat

Dec 04, 2024

Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $48.57 - MarketBeat

Dec 04, 2024

Dec 03, 2024

SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Dec 03, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire

Dec 03, 2024

Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies - Yahoo Finance

Dec 03, 2024

Spyre begins Phase 1 trials for new IBD treatments By Investing.com - Investing.com Canada

Dec 03, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Fmr LLC - MarketBeat

Dec 03, 2024

Dec 02, 2024

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PR Newswire

Dec 02, 2024

Dec 01, 2024

Walleye Capital LLC Increases Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 01, 2024

Nov 30, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat

Nov 30, 2024

Nov 29, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire

Nov 29, 2024

Nov 28, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire

Nov 28, 2024

SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 28, 2024

Nov 27, 2024